LAG3 and melanoma: Currently approved immunotherapy regimens for melanoma from the adjuvant setting to metastatic disease target immune checkpoints, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, e.g., ipilimumab), programmed cell death protein receptor 1 (PD-1, e.g., pembrolizumab and nivolumab), its ligand PD-L1 (e.g., atezolizumab), and lymphocyte-activation gene 3 (LAG3, e.g., relatlimab).